Muenke syndrome

Muenke syndrome is an autosomal dominant craniosynostosis syndrome caused by the gain-of-function FGFR3 variant c.749C>G (p.Pro250Arg), in which premature fusion of one or both coronal sutures produces brachycephaly, midface retrusion and a characteristic pattern of hearing, limb and neurodevelopmental findings

The syndrome occurs in about 1 in 30,000 live births, accounts for roughly 4% of all craniosynostosis and for 25% to 30% of cases with an identified genetic cause, making it one of the commonest single-gene craniosynostosis disorders

Expressivity ranges from isolated coronal synostosis with normal intelligence to multisuture disease with raised intracranial pressure, sensorineural hearing loss and learning disability, and an estimated 6% to 7% of carriers have none of the characteristic features

Terminology and classification

• Muenke syndrome is named after Maximilian Muenke, whose 1997 report linked a unique FGFR3 point mutation to a craniosynostosis phenotype that had previously been grouped with non-syndromic coronal synostosis
• The preferred descriptive synonym is FGFR3-related craniosynostosis, and older records use Muenke nonsyndromic coronal craniosynostosis or FGFR3-associated coronal synostosis, terms that became misleading once hearing loss and limb anomalies were recognised as part of the phenotype
• It is classified as a syndromic craniosynostosis of the FGFR-related group and is separated from Pfeiffer, Apert, Crouzon and Saethre-Chotzen syndromes by its characteristic Pro250Arg variant, its frequent hearing loss and its comparatively mild limb phenotype
• ICD-10 assigns Q87.0 to syndromic craniosynostosis, while ICD-11 places Muenke syndrome at LD24.GY as an Orphanet-attributed narrower entity rather than at the parent code for craniosynostosis
• Cross-references used in interoperability work include Orphanet ORPHA:53271, MONDO:0011274, OMIM 602849, MeSH C537369, UMLS C1864436, GARD 7097 and MedDRA 10088781, and the OMIM number refers to the phenotype rather than to the FGFR3 gene entry
• Different pathogenic variants in the same FGFR3 gene cause achondroplasia, hypochondroplasia, thanatophoric dysplasia, Crouzon syndrome with acanthosis nigricans and SADDAN, so the syndrome cannot be inferred from the gene name alone

History

• In 1997 Muenke and colleagues described families with coronal synostosis who carried a single heterozygous missense change in FGFR3, and the report established Muenke syndrome as a distinct entity separate from the classical FGFR2-related craniosynostoses
• The causal variant was localised to codon 250, where proline is replaced by arginine, and this specific change has since been found in essentially all reported cases across European, North American and Asian cohorts
• Rannan-Eliya and colleagues showed in 2004 that de novo Pro250Arg mutations arise predominantly on the paternal allele, a finding consistent with the paternal-age effect seen in other FGFR3-related conditions
• A 2007 phenotype expansion by Doherty and colleagues added sensorineural and conductive hearing loss, strabismus, broad toes and carpal and tarsal fusion to the core description, and reframed the disorder as a syndromic rather than isolated suture disease
• The first GeneReviews chapter appeared in 2006 and was updated in 2023, while an international multicentre natural history study published in 2016 assembled 110 affected individuals and documented the frequencies of hearing, ocular and developmental complications
• Earlier assumptions that the condition was a purely cosmetic suture problem were revised after longitudinal cohorts showed persistent hearing loss, raised intracranial pressure and learning difficulties in a substantial minority, which shifted practice toward multidisciplinary surveillance
• Craniosynostosis care was consolidated by the 2015 European consensus guideline and its 2021 update, both of which recommend centralised craniofacial teams, protocolised imaging and structured long-term follow-up for syndromic cases such as Muenke syndrome

Epidemiology

• Population estimates converge on approximately 1 in 30,000 live births, which corresponds to a point prevalence of about 3 per 100,000 and places the condition in the rare-disease range used by European reference networks
• Muenke syndrome accounts for about 4% of all craniosynostosis in United States surveillance data and for 25% to 30% of cases with a defined genetic cause, reflecting the high proportion of isolated single-suture cases without an identified mutation
• The sex distribution is equal in clinical series, and no consistent ethnic or geographic predilection has been demonstrated, although ascertainment is higher in centres that offer FGFR3 testing to all children with coronal synostosis
• About one third of affected individuals are the first diagnosed case in their family, whereas two thirds have an affected parent or relative, a pattern that reflects both de novo mutation and the reduced penetrance of the variant
• Hearing loss is reported in roughly 70% of affected individuals in the GeneReviews-based NORD summary, epilepsy in about 20%, macrocephaly in about 5%, and developmental delay or learning problems in a variable but substantial minority
• Penetrance estimates from molecular genetic reviews are higher in females at about 87% than in males at about 76%, and an estimated 6% to 7% of carriers have no craniosynostosis or other recognisable feature
• The condition is distributed worldwide without endemic foci, and its public-health burden is dominated by neonatal craniofacial surgery, hearing rehabilitation and long-term educational support rather than by acute mortality
• Surveillance relies on craniofacial registries, birth-defect surveillance systems and rare-disease databases such as Orphanet and GARD, because no country reports Muenke syndrome as a separately notifiable condition

Pathophysiology

• The syndrome is caused by the heterozygous FGFR3 c.749C>G transition, which substitutes arginine for proline at residue 250 in the extracellular region of the receptor and stabilises the active receptor conformation
• The mutant receptor signals without proportional ligand stimulation and augments FRS2-dependent RAS-MAPK-ERK signalling, which accelerates osteogenic differentiation of cranial suture mesenchyme and narrows the proliferative zone needed for suture patency
• Premature coronal fusion restricts growth perpendicular to the affected suture, so the skull elongates compensatorily in the anteroposterior and basilar dimensions and produces brachycephaly, a shortened skull base and midface retrusion
• The same gain-of-function mechanism in growth-plate chondrocytes explains the limb findings of broad toes, brachydactyly and carpal or tarsal coalition, which are milder than the skeletal dysplasia produced by other FGFR3 variants
• Incomplete penetrance and variable expressivity are not explained by the variant alone and are attributed to modifier genes, stochastic developmental factors and possibly sex-dependent differences in suture biology
• Raised intracranial pressure can arise from a constricted vault even without overt craniosynostosis, and chronic venous hypertension, obstructive sleep apnoea and Chiari malformation are recognised secondary mechanisms in syndromic craniosynostosis

Clinical features

• The hallmark is unilateral or bilateral coronal synostosis, which produces a tall or brachycephalic skull, a flat occiput, hypertelorism, malar flattening and a retruded midface that becomes more apparent with age
• Hearing loss affects about 70% of patients and may be sensorineural, conductive or mixed, while recurrent otitis media and middle-ear effusion are common and can aggravate conductive loss
• Most affected people have normal intelligence, but developmental delay, speech delay, learning disability and attention problems occur in a substantial minority, and epilepsy is reported in approximately 20%
• Ocular findings include strabismus, nystagmus, refractive error and, in severe cases, optic atrophy or exposure keratopathy from proptosis, all of which require serial ophthalmological assessment
• Limb abnormalities are mild compared with other FGFR3 disorders and include broad great toes, short fingers, brachydactyly and carpotarsal fusion that may be asymptomatic or cause stiffness
• Raised intracranial pressure, obstructive sleep apnoea, dental crowding and psychosocial sequelae of altered facial appearance are the main complications, and their frequency rises with multisuture involvement and delayed surgery

Diagnosis

• Diagnosis is suspected in any child with coronal synostosis, especially when sensorineural hearing loss, broad toes or a family history of craniosynostosis coexist, and three-dimensional computed tomography confirms the fused suture and associated skull-base deformity
• Confirmation requires molecular identification of the FGFR3 c.749C>G (p.Pro250Arg) variant by Sanger sequencing, a targeted craniosynostosis panel or exome sequencing, and parental testing distinguishes inherited from de novo cases
• Baseline assessment includes audiometry or auditory brainstem response, tympanometry, ophthalmological examination, developmental and speech evaluation, and polysomnography when sleep-disordered breathing is suspected
• Cranial magnetic resonance imaging is indicated when intracranial hypertension, Chiari malformation or hydrocephalus is suspected, and serial fundoscopy with optical coherence tomography can detect papilloedema in children too young for reliable visual-field testing
• The differential diagnosis includes Pfeiffer, Apert, Crouzon and Saethre-Chotzen syndromes, isolated non-syndromic coronal synostosis, Jackson-Weiss syndrome and other FGFR2 or TWIST1 disorders, each distinguished by its mutation, limb pattern and extracranial features
• Prenatal diagnosis is possible when a parent carries the variant, using chorionic villus sampling or amniocentesis for FGFR3 codon 250, whereas ultrasound alone cannot reliably exclude the syndrome because the cranial phenotype may be mild or absent at birth

Management

• Care is delivered by a craniofacial multidisciplinary team that includes a craniofacial surgeon, paediatric neurosurgeon, geneticist, ophthalmologist, otolaryngologist, audiologist, speech therapist and psychologist, with surveillance intervals determined by age and phenotype
• For significant coronal synostosis, fronto-orbital advancement with cranial vault remodelling is typically performed between 3 and 6 months of age, while endoscopic strip craniectomy followed by helmet therapy is an alternative offered before 3 months in selected centres
• Surgery aims to release the fused suture, normalise vault shape and reduce intracranial pressure, and secondary or tertiary contouring may be required as the child grows, particularly after early single-stage procedures
• Hearing management includes audiological monitoring, hearing aids for persistent loss, myringotomy tubes for recurrent effusion and treatment of otitis media, because uncorrected hearing loss compounds speech and language delay
• Strabismus surgery is considered after the craniofacial procedure, and proptosis requires lubricants and corneal protection, with urgent ophthalmological review for exposure keratopathy or optic disc swelling
• Epilepsy is treated with standard antiseizure drugs such as levetiracetam or valproate according to seizure type, and developmental therapy, educational support and behavioural intervention address learning and attention difficulties
• Genetic counselling explains the 50% transmission risk for an affected parent, the possibility of reduced penetrance in a carrier parent and the low recurrence risk when the proband carries a de novo variant
• Prognosis for survival is generally good, but neurodevelopmental outcome, hearing and visual function and the need for revision surgery vary widely, and structured follow-up through adolescence is recommended by the 2021 craniosynostosis guideline

Research and controversies

• Preclinical work targets the constitutive FGFR3 signal with MEK or ERK inhibitors and with FGFR-selective tyrosine kinase inhibitors, aiming to delay suture fusion rather than replace surgery, but no agent has entered routine clinical use
• The optimal timing and technique of vault surgery remain contested, with proponents of early endoscopic strip craniectomy citing lower blood loss and shorter stay and proponents of open vault remodelling citing better long-term shape control in multisuture disease
• Long-term studies report persistent elevations in intracranial pressure and a clinically meaningful burden of hearing, speech and learning problems, which argues for surveillance beyond the surgical episode rather than discharge after successful vault expansion
• Genotype-phenotype studies have not found a consistent modifier that predicts severity, so counselling still relies on family-specific experience and on serial clinical assessment rather than on a molecular prognostic score
• Patient organisations and rare-disease networks, including NORD and the Genetic and Rare Diseases Information Center, provide family support and registries, and international natural-history collaboration is seen as the main route to better evidence for adult outcomes